Zante Greg

Chief Financial Officer

1 company

Average

Trades Analyzed

12M Win Rate

40.0%

Avg 3M Return

+5.5%

Avg 12M Return

-42.1%

Zante Greg is a Chief Financial Officer at Viking Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 27 sells.

Estimated insider holdings value: $7.0M based on current market prices.

Holdings by Company

VKTXJan 5, 2026

Current Shares215.6K

Value$6.98M

Net Activity-615,279

Bought: 0Sold: 615.3K

Showing 10 filings

Date	Ticker	Role	Type	Shares	Price	Value	Chg%	3M	12M
Jan 5, 2026	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sell	57,661	$32.90	$1,896,969.39	-6.7%	+5.6%	-
Oct 28, 2025	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sell	6,185	$35.00	$216,480.57	-3.4%	-9.2%	-
Jul 3, 2025	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sell	4,266	$27.76	$118,428.43	-2.5%	-2.9%	-
Jan 6, 2025	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sell	50,309	$42.75	$2,150,594.66	-13.0%	-50.0%	-24.1%
Oct 28, 2024	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sale+OE	131,687	$76.61	$10,089,164.06	-8.3%	-55.1%	-53.1%
Jul 30, 2024	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sell	16,136	$57.15	$922,212.06	-2.8%	+31.8%	-40.4%
May 3, 2024	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sale+OE	66,756	$74.69	$4,986,007.97	-7.9%	-29.0%	-61.9%
Jan 4, 2024	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sell	15,000	$17.90	$268,500.00	-7.7%	+322.2%	+130.8%
Apr 17, 2023	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sale+OE	7,500	$20.00	$150,000.00	-4.8%	-21.1%	+246.2%
Apr 12, 2023	VKTX Viking Therapeutics, Inc.	Chief Financial Officer	Sale+OE	97,839	$18.00	$1,761,310.29	-24.7%	-9.8%	+299.7%